HGSI Human Genome: Expect BLA acceptance near term -
Think Equity expects the next Benlysta related catalyst, FDA acceptance of the BLA, to occur in the next week or two, initiating a busy back half of the year for HGSI that they believe will culminate in the first FDA approved drug to treat lupus in over 50 years. Firm believes the current stock price overestimates the risk of regulatory delay and a number of derisking events will drive the shares through the 52-week high in the coming months.
No comments:
Post a Comment